Botulinum  ||| S:0 E:10 ||| FW
neurotoxin  ||| S:10 E:21 ||| FW
type  ||| S:21 E:26 ||| FW
A-ABO  ||| S:26 E:32 ||| FW
( ||| S:32 E:33 ||| -LRB-
Dysport ||| S:33 E:40 ||| NNP
) ||| S:40 E:41 ||| -RRB-
:  ||| S:41 E:43 ||| :
clinical  ||| S:43 E:52 ||| JJ
indications  ||| S:52 E:64 ||| NNS
and  ||| S:64 E:68 ||| CC
practice  ||| S:68 E:77 ||| NN
guide  ||| S:77 E:83 ||| NN
The  ||| S:83 E:87 ||| DT
key  ||| S:87 E:91 ||| JJ
points  ||| S:91 E:98 ||| NNS
to  ||| S:98 E:101 ||| TO
remember  ||| S:101 E:110 ||| VB
about  ||| S:110 E:116 ||| IN
abobotulinumtoxinA  ||| S:116 E:135 ||| NNS
are  ||| S:135 E:139 ||| VBP
as  ||| S:139 E:142 ||| RB
follows ||| S:142 E:149 ||| VBZ
:  ||| S:149 E:151 ||| :
BoNTA-ABO  ||| S:151 E:161 ||| NNP
( ||| S:161 E:162 ||| -LRB-
abobotulinumtoxinA  ||| S:162 E:181 ||| NNP
[ ||| S:181 E:182 ||| -LRB-
Dysport ||| S:182 E:189 ||| NNP
] ||| S:189 E:190 ||| -RRB-
;  ||| S:190 E:192 ||| :
Medicis  ||| S:192 E:200 ||| NNP
Aesthetics ||| S:200 E:210 ||| NNP
,  ||| S:210 E:212 ||| ,
Scottsdale ||| S:212 E:222 ||| NNP
,  ||| S:222 E:224 ||| ,
AZ ||| S:224 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
and  ||| S:228 E:232 ||| CC
BoNTA-ONA  ||| S:232 E:242 ||| NNP
( ||| S:242 E:243 ||| -LRB-
onabotulinumtoxin  ||| S:243 E:261 ||| VB
A  ||| S:261 E:263 ||| DT
[ ||| S:263 E:264 ||| -LRB-
Botox  ||| S:264 E:270 ||| NNP
Cosmetic ||| S:270 E:278 ||| NNP
] ||| S:278 E:279 ||| -RRB-
;  ||| S:279 E:281 ||| :
Allergan ||| S:281 E:289 ||| NNP
,  ||| S:289 E:291 ||| ,
Irvine ||| S:291 E:297 ||| NNP
,  ||| S:297 E:299 ||| ,
CA ||| S:299 E:301 ||| NNP
)  ||| S:301 E:303 ||| -RRB-
are  ||| S:303 E:307 ||| VBP
both  ||| S:307 E:312 ||| DT
derivatives  ||| S:312 E:324 ||| NNS
of  ||| S:324 E:327 ||| IN
botulinum  ||| S:327 E:337 ||| JJ
toxin  ||| S:337 E:343 ||| NN
A  ||| S:343 E:345 ||| DT
produced  ||| S:345 E:354 ||| VBN
from  ||| S:354 E:359 ||| IN
different  ||| S:359 E:369 ||| JJ
strains  ||| S:369 E:377 ||| NNS
of  ||| S:377 E:380 ||| IN
the  ||| S:380 E:384 ||| DT
bacterium  ||| S:384 E:394 ||| NN
Clostridium  ||| S:394 E:406 ||| NNP
botulinum  ||| S:406 E:416 ||| NN
through  ||| S:416 E:424 ||| IN
proprietary  ||| S:424 E:436 ||| JJ
manufacturing  ||| S:436 E:450 ||| NN
processes ||| S:450 E:459 ||| NNS
,  ||| S:459 E:461 ||| ,
and  ||| S:461 E:465 ||| CC
both  ||| S:465 E:470 ||| DT
are  ||| S:470 E:474 ||| VBP
approved  ||| S:474 E:483 ||| VBN
by  ||| S:483 E:486 ||| IN
the  ||| S:486 E:490 ||| DT
US  ||| S:490 E:493 ||| NNP
Food  ||| S:493 E:498 ||| NNP
and  ||| S:498 E:502 ||| CC
Drug  ||| S:502 E:507 ||| NNP
Administration  ||| S:507 E:522 ||| NNP
( ||| S:522 E:523 ||| -LRB-
FDA ||| S:523 E:526 ||| NNP
) ||| S:526 E:527 ||| -RRB-
.  ||| S:527 E:529 ||| .
BoNTA-ABO  ||| S:529 E:539 ||| NNP
and  ||| S:539 E:543 ||| CC
BoNTA-ONA ||| S:543 E:552 ||| JJ
,  ||| S:552 E:554 ||| ,
which  ||| S:554 E:560 ||| WDT
are  ||| S:560 E:564 ||| VBP
both  ||| S:564 E:569 ||| DT
type  ||| S:569 E:574 ||| NN
A  ||| S:574 E:576 ||| DT
botulinum  ||| S:576 E:586 ||| JJ
toxins ||| S:586 E:592 ||| NN
,  ||| S:592 E:594 ||| ,
should  ||| S:594 E:601 ||| MD
be  ||| S:601 E:604 ||| VB
further  ||| S:604 E:612 ||| JJ
differentiated  ||| S:612 E:627 ||| NN
from  ||| S:627 E:632 ||| IN
Myobloc  ||| S:632 E:640 ||| NNP
( ||| S:640 E:641 ||| -LRB-
Solstice  ||| S:641 E:650 ||| NNP
Neurosciences ||| S:650 E:663 ||| NNP
,  ||| S:663 E:665 ||| ,
San  ||| S:665 E:669 ||| NNP
Francisco ||| S:669 E:678 ||| NNP
,  ||| S:678 E:680 ||| ,
CA ||| S:680 E:682 ||| NNP
) ||| S:682 E:683 ||| -RRB-
,  ||| S:683 E:685 ||| ,
which  ||| S:685 E:691 ||| WDT
is  ||| S:691 E:694 ||| VBZ
the  ||| S:694 E:698 ||| DT
only  ||| S:698 E:703 ||| JJ
FDA-approved  ||| S:703 E:716 ||| JJ
type  ||| S:716 E:721 ||| NN
B  ||| S:721 E:723 ||| NN
botulinum  ||| S:723 E:733 ||| NN
toxin ||| S:733 E:738 ||| NN
.  ||| S:738 E:740 ||| .
BoNTA-ABO ||| S:740 E:749 ||| NNP
,  ||| S:749 E:751 ||| ,
as  ||| S:751 E:754 ||| RB
with  ||| S:754 E:759 ||| IN
other  ||| S:759 E:765 ||| JJ
derivatives  ||| S:765 E:777 ||| NNS
of  ||| S:777 E:780 ||| IN
botulinum  ||| S:780 E:790 ||| JJ
toxin ||| S:790 E:795 ||| NN
,  ||| S:795 E:797 ||| ,
produces  ||| S:797 E:806 ||| VBZ
a  ||| S:806 E:808 ||| DT
chemodenervation  ||| S:808 E:825 ||| NN
of  ||| S:825 E:828 ||| IN
the  ||| S:828 E:832 ||| DT
muscle  ||| S:832 E:839 ||| NN
by  ||| S:839 E:842 ||| IN
preventing  ||| S:842 E:853 ||| VBG
the  ||| S:853 E:857 ||| DT
release  ||| S:857 E:865 ||| NN
and  ||| S:865 E:869 ||| CC
binding  ||| S:869 E:877 ||| JJ
of  ||| S:877 E:880 ||| IN
acetylcholine  ||| S:880 E:894 ||| NN
at  ||| S:894 E:897 ||| IN
the  ||| S:897 E:901 ||| DT
neuromuscular  ||| S:901 E:915 ||| JJ
endplate ||| S:915 E:923 ||| NN
.  ||| S:923 E:925 ||| .
The  ||| S:925 E:929 ||| DT
paralytic  ||| S:929 E:939 ||| JJ
effect  ||| S:939 E:946 ||| NN
of  ||| S:946 E:949 ||| IN
BoNTA-ABO ||| S:949 E:958 ||| NNP
,  ||| S:958 E:960 ||| ,
as  ||| S:960 E:963 ||| RB
with  ||| S:963 E:968 ||| IN
other  ||| S:968 E:974 ||| JJ
derivatives  ||| S:974 E:986 ||| NNS
of  ||| S:986 E:989 ||| IN
botulinum  ||| S:989 E:999 ||| JJ
toxin ||| S:999 E:1004 ||| NN
,  ||| S:1004 E:1006 ||| ,
produces  ||| S:1006 E:1015 ||| VBZ
a  ||| S:1015 E:1017 ||| DT
relaxation  ||| S:1017 E:1028 ||| NN
of  ||| S:1028 E:1031 ||| IN
the  ||| S:1031 E:1035 ||| DT
underlying  ||| S:1035 E:1046 ||| JJ
muscle  ||| S:1046 E:1053 ||| NN
with  ||| S:1053 E:1058 ||| IN
the  ||| S:1058 E:1062 ||| DT
associated  ||| S:1062 E:1073 ||| JJ
benefit  ||| S:1073 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
reducing  ||| S:1084 E:1093 ||| VBG
dynamic  ||| S:1093 E:1101 ||| JJ
rhytids  ||| S:1101 E:1109 ||| NN
of  ||| S:1109 E:1112 ||| IN
the  ||| S:1112 E:1116 ||| DT
overlying  ||| S:1116 E:1126 ||| JJ
skin ||| S:1126 E:1130 ||| NN
.  ||| S:1130 E:1132 ||| .
BoNTA-ABO  ||| S:1132 E:1142 ||| JJ
units  ||| S:1142 E:1148 ||| NNS
are  ||| S:1148 E:1152 ||| VBP
not  ||| S:1152 E:1156 ||| RB
interchangeable  ||| S:1156 E:1172 ||| VBN
with  ||| S:1172 E:1177 ||| IN
BoNTA-ONA  ||| S:1177 E:1187 ||| JJ
units ||| S:1187 E:1192 ||| NNS
.  ||| S:1192 E:1194 ||| .
An  ||| S:1194 E:1197 ||| DT
understanding  ||| S:1197 E:1211 ||| NN
of  ||| S:1211 E:1214 ||| IN
the  ||| S:1214 E:1218 ||| DT
proper  ||| S:1218 E:1225 ||| JJ
dosing  ||| S:1225 E:1232 ||| NN
and  ||| S:1232 E:1236 ||| CC
familiarity  ||| S:1236 E:1248 ||| NN
with  ||| S:1248 E:1253 ||| IN
the  ||| S:1253 E:1257 ||| DT
use  ||| S:1257 E:1261 ||| NN
of  ||| S:1261 E:1264 ||| IN
either  ||| S:1264 E:1271 ||| DT
botulinum  ||| S:1271 E:1281 ||| JJ
toxin  ||| S:1281 E:1287 ||| NN
in  ||| S:1287 E:1290 ||| IN
aesthetic  ||| S:1290 E:1300 ||| JJ
applications  ||| S:1300 E:1313 ||| NNS
is  ||| S:1313 E:1316 ||| VBZ
required  ||| S:1316 E:1325 ||| VBN
to  ||| S:1325 E:1328 ||| TO
produce  ||| S:1328 E:1336 ||| VB
results  ||| S:1336 E:1344 ||| NNS
that  ||| S:1344 E:1349 ||| WDT
are  ||| S:1349 E:1353 ||| VBP
both  ||| S:1353 E:1358 ||| DT
safe  ||| S:1358 E:1363 ||| JJ
and  ||| S:1363 E:1367 ||| CC
consistent ||| S:1367 E:1377 ||| JJ
.  ||| S:1377 E:1379 ||| .
Spread  ||| S:1379 E:1386 ||| NN
of  ||| S:1386 E:1389 ||| IN
the  ||| S:1389 E:1393 ||| DT
toxin  ||| S:1393 E:1399 ||| NN
is  ||| S:1399 E:1402 ||| VBZ
dependent  ||| S:1402 E:1412 ||| JJ
on  ||| S:1412 E:1415 ||| IN
solution  ||| S:1415 E:1424 ||| NN
volume  ||| S:1424 E:1431 ||| NN
and  ||| S:1431 E:1435 ||| CC
injection  ||| S:1435 E:1445 ||| NN
technique  ||| S:1445 E:1455 ||| NN
( ||| S:1455 E:1456 ||| -LRB-
physically  ||| S:1456 E:1467 ||| RB
pushing  ||| S:1467 E:1475 ||| VBG
the  ||| S:1475 E:1479 ||| DT
toxin  ||| S:1479 E:1485 ||| NN
from  ||| S:1485 E:1490 ||| IN
the  ||| S:1490 E:1494 ||| DT
area  ||| S:1494 E:1499 ||| NN
of  ||| S:1499 E:1502 ||| IN
injection ||| S:1502 E:1511 ||| NN
) ||| S:1511 E:1512 ||| -RRB-
.  ||| S:1512 E:1514 ||| .
Diffusion  ||| S:1514 E:1524 ||| NNP
of  ||| S:1524 E:1527 ||| IN
the  ||| S:1527 E:1531 ||| DT
toxin  ||| S:1531 E:1537 ||| NN
is  ||| S:1537 E:1540 ||| VBZ
largely  ||| S:1540 E:1548 ||| RB
dependent  ||| S:1548 E:1558 ||| JJ
on  ||| S:1558 E:1561 ||| IN
toxin  ||| S:1561 E:1567 ||| NN
dose  ||| S:1567 E:1572 ||| NN
and  ||| S:1572 E:1576 ||| CC
receptor  ||| S:1576 E:1585 ||| JJ
concentration ||| S:1585 E:1598 ||| NN
;  ||| S:1598 E:1600 ||| :
unbound  ||| S:1600 E:1608 ||| JJ
toxin  ||| S:1608 E:1614 ||| NN
moves  ||| S:1614 E:1620 ||| NNS
down  ||| S:1620 E:1625 ||| IN
a  ||| S:1625 E:1627 ||| DT
concentration  ||| S:1627 E:1641 ||| NN
gradient ||| S:1641 E:1649 ||| NN
.  ||| S:1649 E:1651 ||| .
Beyond  ||| S:1651 E:1658 ||| IN
the  ||| S:1658 E:1662 ||| DT
treatment  ||| S:1662 E:1672 ||| NN
of  ||| S:1672 E:1675 ||| IN
glabellar  ||| S:1675 E:1685 ||| JJ
rhytids ||| S:1685 E:1692 ||| NN
,  ||| S:1692 E:1694 ||| ,
there  ||| S:1694 E:1700 ||| EX
are  ||| S:1700 E:1704 ||| VBP
few ||| S:1704 E:1707 ||| JJ
,  ||| S:1707 E:1709 ||| ,
if  ||| S:1709 E:1712 ||| IN
any ||| S:1712 E:1715 ||| DT
,  ||| S:1715 E:1717 ||| ,
randomized ||| S:1717 E:1727 ||| NN
,  ||| S:1727 E:1729 ||| ,
double  ||| S:1729 E:1736 ||| RB
blind ||| S:1736 E:1741 ||| JJ
,  ||| S:1741 E:1743 ||| ,
placebo-controlled  ||| S:1743 E:1762 ||| JJ
studies  ||| S:1762 E:1770 ||| NNS
on  ||| S:1770 E:1773 ||| IN
the  ||| S:1773 E:1777 ||| DT
aesthetic  ||| S:1777 E:1787 ||| JJ
uses  ||| S:1787 E:1792 ||| NNS
of  ||| S:1792 E:1795 ||| IN
BoNTA-ABO ||| S:1795 E:1804 ||| JJ
.  ||| S:1804 E:1806 ||| .
This  ||| S:1806 E:1811 ||| DT
guide  ||| S:1811 E:1817 ||| NN
summarizes  ||| S:1817 E:1828 ||| NNS
what  ||| S:1828 E:1833 ||| WP
is  ||| S:1833 E:1836 ||| VBZ
known  ||| S:1836 E:1842 ||| VBN
and  ||| S:1842 E:1846 ||| CC
serves  ||| S:1846 E:1853 ||| VBZ
as  ||| S:1853 E:1856 ||| IN
a  ||| S:1856 E:1858 ||| DT
basis  ||| S:1858 E:1864 ||| NN
for  ||| S:1864 E:1868 ||| IN
clinical  ||| S:1868 E:1877 ||| JJ
use  ||| S:1877 E:1881 ||| NN
and  ||| S:1881 E:1885 ||| CC
continued  ||| S:1885 E:1895 ||| JJ
understanding ||| S:1895 E:1908 ||| NN
.  ||| S:1908 E:1910 ||| .
